iTeos Therapeutics (NASDAQ:ITOS) Given New $19.00 Price Target at Wells Fargo & Company

iTeos Therapeutics (NASDAQ:ITOS) had its price target decreased by equities researchers at Wells Fargo & Company from $31.00 to $19.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 161.71% from the company’s previous close.

Several other equities analysts also recently commented on ITOS. Wedbush reissued an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Price Performance

Shares of ITOS remained flat at $7.26 during midday trading on Thursday. The stock had a trading volume of 20,387 shares, compared to its average volume of 442,673. iTeos Therapeutics has a one year low of $7.13 and a one year high of $18.75. The company has a market cap of $265.24 million, a PE ratio of -2.30 and a beta of 1.37. The company’s 50 day moving average price is $8.63 and its two-hundred day moving average price is $12.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current year.

Insider Transactions at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC raised its stake in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new stake in iTeos Therapeutics in the 3rd quarter valued at about $31,000. China Universal Asset Management Co. Ltd. lifted its holdings in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the last quarter. Virtu Financial LLC bought a new position in iTeos Therapeutics during the third quarter worth about $102,000. Finally, Quest Partners LLC raised its position in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after purchasing an additional 9,934 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.